Therapeutic Potential of Cannabidiol, Cannabidiolic Acid, and Cannabidiolic Acid Methyl Ester as Treatments for Nausea and Vomiting

Cannabis Cannabinoid Res. 2021 Aug;6(4):266-274. doi: 10.1089/can.2021.0041. Epub 2021 Jun 11.


Introduction: Nausea and vomiting are the most distressing symptoms reported by oncology patients undergoing anticancer treatment. With the currently available treatments, vomiting and especially nausea remain problematic, highlighting the need for alternative treatments. Discussion: Here we review in vitro and in vivo evidence for the effectiveness of the nonpsychoactive cannabinoid cannabidiol (CBD) in managing nausea and vomiting. In addition, we also review the evidence for CBD's acidic precursor, cannabidiolic acid (CBDA), and a methylated version of CBDA (CBDA-ME) in these phenomena. Finally, we explore the potential role of CBD in the treatment of cannabinoid hyperemesis syndrome. Conclusions: CBD has demonstrated efficacy in reducing nausea and vomiting, with CBDA and CBDA-ME being more potent. The data suggest a need for these compounds to be evaluated in clinical trials for their ability to reduce nausea and/or vomiting.

Keywords: CBD; anti-emetic; behavior; cannabidiol; phytocannabinoids.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Cannabidiol* / therapeutic use
  • Cannabinoids* / therapeutic use
  • Esters
  • Humans
  • Nausea / chemically induced
  • Vomiting / chemically induced


  • Cannabinoids
  • Esters
  • Cannabidiol
  • cannabidiolic acid

Grants and funding